

The 2023-2028 Outlook for Rare Disease Drugs in India

https://marketpublishers.com/r/2C48946CF26FEN.html

Date: September 2022

Pages: 401

Price: US\$ 595.00 (Single User License)

ID: 2C48946CF26FEN

Abstracts

This study covers the latent demand outlook for rare disease drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-?-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for rare disease drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and longrun view, irrespective of the players or products involved.

In this report we define the sales of rare disease drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AB Science, Acceleron Pharma & Celgene, Acer Therapeutics, Actavis Generics, Actelion Pharmaceuticals, Actinium Pharmaceuticals, Adaptimmune, Aduro BioTech, Advanced Accelerator Applications, Advantagene, Advaxis, Advenchen Laboratories, Affimed Therapeutics & Merck, Agenus, Agios Pharmaceuticals, Akashi Therapeutics, Akcea Therapeutics, Alcobra, Alexion Pharmaceuticals, Alkeus Pharmaceuticals, Allergan, Alnylam Pharmaceuticals, Ambit Biosciences, AmerisourceBergen Corporation, Amgen, Amicus Therapeutics, Andarix Pharmaceuticals, Angimmune, AngioChem, AntiVirus Therapeutics, Applied Genetic Technologies, Araim Pharmaceuticals, Arch Biopartners, arGentis Pharmaceuticals,



Ariad Pharmaceuticals, Armagen Technologies, ARMGO Pharma, AROG Pharmaceuticals, ArQule, Array BioPharma, Arrowhead Research, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Atox Bio, aTyr Pharma, Baxalta, Bayer Healthcare, Belrose Pharmaceuticals, BerGenBio, Bioblast Pharma, BioCryst Pharmaceuticals, Biodel, Biogen, BioInvent International, BioLineRX, BioMarin Pharmaceutical, BioNTech, Bio-Path Holdings, Biotest Pharmaceuticals, Blaze Bioscience, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Burzynski Research Institute, Caladrius Biosciences, Cancer Advances, Capricor Therapeutics, Cardinal Health, CASI Pharmaceuticals, Catabasis Pharmaceuticals, Cavion, Celator Pharmaceuticals, Celgene Corporation, Cell Medica, CEL-SCI, CELSION, Celtaxsys, Cempra Pharmaceuticals, CerRx, Cerulean Pharma, ChemoCentryx, Chugai Pharma, Cidara Therapeutics, Cleave Biosciences, Clementia Pharmaceuticals, Clinuvel, Clovis Oncology, Confluence Pharmaceuticals, Corbus Pharmaceuticals, Cornerstone Pharmaceuticals, Cortice Biosciences, Critical Outcome Technologies, Curis, Cyclacel, CymaBay Therapeutics, CytRx, Daiichi Sankyo, Deciphera Pharmaceuticals, Delcath Systems, DelMar Pharmaceuticals, Diffusion Pharmaceuticals, Dimension Therapeutics, Diurnal, DNAtrix, Eddingpharm, Edimer Pharmaceuticals, Edison Pharmaceuticals, Eiger BioPharmaceuticals, Eisai, Eleison Pharmaceuticals, Eli Lilly, EMD Serono & Pfizer, Emergent BioSolutions, Emmaus Medical, Epitopoietic Research, Epizyme, EryDel, Escala Therapeutics, Essentialis, Five Prime Therapeutics, Fortress Biotech, Gamida Cell, Gem Pharmaceuticals, Gen Sight Biologics, GenSpera, Genzyme, Gilead Sciences, GlaxoSmithKline, Gliknik, Global Blood Therapeutics, GlycoMimetics, Golden Biotechnology, Gradalis, Grifols Therapeutics, GW Pharma, Halozyme Therapeutics, Hanmi, Hoffmann-La Roche, Horizon Pharma, Idera Pharmaceuticals, Ignyta, Immatics Biotechnologies, Immune Design, Immunocellular Therapeutics, Immunogen, Immunomedics, Immunovaccine Technologies, Incyte, Infinity Pharmaceuticals, InnoPharma, Insmed, Insys Therapeutics, Ionis Pharmaceuticals, Ipsen Biopharmaceuticals, IRX Therapeutics, Janssen Biotech, jCyte, Juno Therapeutics, Karyopharm Therapeutics, Kevelt, Kyowa Kirin USA, LeafBio, Lexicon Pharmaceuticals, Lion Biotechnologies, LipimetiX Development, MabVax Therapeutics, Marathon Pharmaceuticals, Marina Biotech, Mast Therapeutics, McKesson Corporation, MedImmune, MEI Pharma, Merck & Company, Millendo Therapeutics, Millennium Pharmaceuticals, Milo Biotechnology, Minneamrita Therapeutics, Mirati Therapeutics, Momenta Pharmaceuticals, MorphoSys, Nektar Therapeutics, NeOnc Technologies, Neuren Pharmaceuticals, Neurolixis, Neurotech USA, NGM Biopharmaceuticals, NightstaRx, Nivalis Therapeutics, NKT Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, Ocata Therapeutics, Omeros, On Target Laboratories, Oncolytics Biotech, OncoMed Pharmaceuticals, Onconova Therapeutics, OncoPep, Opko Biologics, OSE Pharma, Otsuka Pharmaceutical, OXiGENE, Patagonia



Pharmaceuticals, Peregrine Pharmaceuticals, Pfizer, Pharmacyclics, PharmaCyte Biotech, PharmaEssentia, Corporation, PharmaMar USA, Plexxikon, PNP Therapeutics, Polaris Pharmaceuticals, Polynoma, Prana Biotechnology, Precision Biologics, Progenics Pharmaceuticals, Prolong Pharmaceuticals, Promedior, ProMetic Biotherapeutics, ProNAi Therapeutics, ProQR Therapeutics, Protalex, Provectus Pharmaceuticals, PTC Therapeutics, QLT, Quest PharmaTech, Qurient, Raptor Pharmaceutical, Rebiotx, Regeneron Pharmaceuticals, Regulus Therapeutics & Sanofi US, Retrophin, RetroSense Therapeutics, ReveraGen Biopharma, Rexahn Pharmaceuticals, Rhythm Metabolics, Rigel Pharmaceuticals, River Vision, Roche, Sanofi, Santhera Pharmaceuticals, Sarepta Therapeutics, Savara Pharmaceuticals, Seattle Genetics, Selexys Pharmaceuticals, SELLAS Life Sciences, Sequella, Seres Health, Shire, SIGA Technologies, Sigma-Tau Pharmaceuticals, SillaJen Biotherapeutics, Soligenix, Soricimed Biopharma, Spark Therapeutics, StemcentRx, Stemline Therapeutics, Sun Biopharma, Takeda Pharmaceuticals, Tapimmune, Tarix Orphan, Tesaro, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, TG Therapeutics, Tiziana Life Sciences, Tocagen, Tolero Pharmaceuticals, Tracon Pharmaceuticals, TransDerm, Triphase Research & Development, Ultragenyx Pharmaceutical, UniQure, UroGen, Vascular Biogenics, VentiRx Pharmaceuticals, Verastem, Vertex Pharmaceuticals, Viamet Pharmaceuticals, Vicus Therapeutics, Viralytics, Viventia Biotech, VivoLux, Vtesse, Wilson Therapeutics, Xeris Pharmaceuticals, XOMA, Ziopharm Oncology, Zogenix, and Zywie. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).



Contents

1 INTRODUCTION

- 1.1 OVERVIEW
- 1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
- 1.3 THE METHODOLOGY
- 1.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
- 1.3.2 STEP 2. FILTERING AND SMOOTHING
- 1.3.3 STEP 3. FILLING IN MISSING VALUES
- 1.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
- 1.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
- 1.3.6 STEP 6. AGGREGATION AND BENCHMARKING
- 1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
 - 1.4.1 CATEGORY DEFINITION
 - 1.4.2 UNITS
 - 1.4.3 METHODOLOGY

2 SUMMARY OF FINDINGS

- 2.1 LATENT DEMAND IN INDIA
- 2.2 TOP 100 CITIES SORTED BY RANK
- 2.3 LATENT DEMAND BY YEAR IN INDIA

3 ANDAMAN & NICOBAR ISLANDS

- 3.1 LATENT DEMAND BY YEAR ANDAMAN & NICOBAR ISLANDS
- 3.2 CITIES SORTED BY RANK ANDAMAN & NICOBAR ISLANDS
- 3.3 CITIES SORTED BY DISTRICT ANDAMAN & NICOBAR ISLANDS

4 ANDHRA PRADESH

- 4.1 LATENT DEMAND BY YEAR ANDHRA PRADESH
- 4.2 CITIES SORTED BY RANK ANDHRA PRADESH
- 4.3 CITIES SORTED BY DISTRICT ANDHRA PRADESH

5 ARUNACHAL PRADESH

5.1 LATENT DEMAND BY YEAR - ARUNACHAL PRADESH



5.2 CITIES SORTED BY RANK - ARUNACHAL PRADESH 5.3 CITIES SORTED BY DISTRICT - ARUNACHAL PRADESH

6 ASSAM

- 6.1 LATENT DEMAND BY YEAR ASSAM
- 6.2 CITIES SORTED BY RANK ASSAM
- 6.3 CITIES SORTED BY DISTRICT ASSAM

7 BIHAR

- 7.1 LATENT DEMAND BY YEAR BIHAR
- 7.2 CITIES SORTED BY RANK BIHAR
- 7.3 CITIES SORTED BY DISTRICT BIHAR

8 CHANDIGARH

- 8.1 LATENT DEMAND BY YEAR CHANDIGARH
- 8.2 CITIES SORTED BY RANK CHANDIGARH
- 8.3 CITIES SORTED BY DISTRICT CHANDIGARH

9 CHHATTISGARH

- 9.1 LATENT DEMAND BY YEAR CHHATTISGARH
- 9.2 CITIES SORTED BY RANK CHHATTISGARH
- 9.3 CITIES SORTED BY DISTRICT CHHATTISGARH

10 DADRA & NAGAR HAVELI

- 10.1 LATENT DEMAND BY YEAR DADRA & NAGAR HAVELI
- 10.2 CITIES SORTED BY RANK DADRA & NAGAR HAVELI
- 10.3 CITIES SORTED BY DISTRICT DADRA & NAGAR HAVELI

11 DAMAN & DIU

- 11.1 LATENT DEMAND BY YEAR DAMAN & DIU
- 11.2 CITIES SORTED BY RANK DAMAN & DIU
- 11.3 CITIES SORTED BY DISTRICT DAMAN & DIU



12 DELHI

- 12.1 LATENT DEMAND BY YEAR DELHI
- 12.2 CITIES SORTED BY RANK DELHI
- 12.3 CITIES SORTED BY DISTRICT DELHI

13 GOA

- 13.1 LATENT DEMAND BY YEAR GOA
- 13.2 CITIES SORTED BY RANK GOA
- 13.3 CITIES SORTED BY DISTRICT GOA

14 GUJARAT

- 14.1 LATENT DEMAND BY YEAR GUJARAT
- 14.2 CITIES SORTED BY RANK GUJARAT
- 14.3 CITIES SORTED BY DISTRICT GUJARAT

15 HARYANA

- 15.1 LATENT DEMAND BY YEAR HARYANA
- 15.2 CITIES SORTED BY RANK HARYANA
- 15.3 CITIES SORTED BY DISTRICT HARYANA

16 HIMACHAL PRADESH

- 16.1 LATENT DEMAND BY YEAR HIMACHAL PRADESH
- 16.2 CITIES SORTED BY RANK HIMACHAL PRADESH
- 16.3 CITIES SORTED BY DISTRICT HIMACHAL PRADESH

17 JAMMU & KASHMIR

- 17.1 LATENT DEMAND BY YEAR JAMMU & KASHMIR
- 17.2 CITIES SORTED BY RANK JAMMU & KASHMIR
- 17.3 CITIES SORTED BY DISTRICT JAMMU & KASHMIR

18 JHARKHAND

18.1 LATENT DEMAND BY YEAR - JHARKHAND



18.2 CITIES SORTED BY RANK - JHARKHAND 18.3 CITIES SORTED BY DISTRICT - JHARKHAND

19 KARNATAKA

- 19.1 LATENT DEMAND BY YEAR KARNATAKA
- 19.2 CITIES SORTED BY RANK KARNATAKA
- 19.3 CITIES SORTED BY DISTRICT KARNATAKA

20 KERALA

- 20.1 LATENT DEMAND BY YEAR KERALA
- 20.2 CITIES SORTED BY RANK KERALA
- 20.3 CITIES SORTED BY DISTRICT KERALA

21 LAKSHADWEEP

- 21.1 LATENT DEMAND BY YEAR LAKSHADWEEP
- 21.2 CITIES SORTED BY RANK LAKSHADWEEP
- 21.3 CITIES SORTED BY DISTRICT LAKSHADWEEP

22 MADHYA PRADESH

- 22.1 LATENT DEMAND BY YEAR MADHYA PRADESH
- 22.2 CITIES SORTED BY RANK MADHYA PRADESH
- 22.3 CITIES SORTED BY DISTRICT MADHYA PRADESH

23 MAHARASHTRA

- 23.1 LATENT DEMAND BY YEAR MAHARASHTRA
- 23.2 CITIES SORTED BY RANK MAHARASHTRA
- 23.3 CITIES SORTED BY DISTRICT MAHARASHTRA

24 MANIPUR

- 24.1 LATENT DEMAND BY YEAR MANIPUR
- 24.2 CITIES SORTED BY RANK MANIPUR
- 24.3 CITIES SORTED BY DISTRICT MANIPUR



25 MEGHALAYA

- 25.1 LATENT DEMAND BY YEAR MEGHALAYA
- 25.2 CITIES SORTED BY RANK MEGHALAYA
- 25.3 CITIES SORTED BY DISTRICT MEGHALAYA

26 MIZORAM

- 26.1 LATENT DEMAND BY YEAR MIZORAM
- 26.2 CITIES SORTED BY RANK MIZORAM
- 26.3 CITIES SORTED BY DISTRICT MIZORAM

27 NAGALAND

- 27.1 LATENT DEMAND BY YEAR NAGALAND
- 27.2 CITIES SORTED BY RANK NAGALAND
- 27.3 CITIES SORTED BY DISTRICT NAGALAND

28 ORISSA

- 28.1 LATENT DEMAND BY YEAR ORISSA
- 28.2 CITIES SORTED BY RANK ORISSA
- 28.3 CITIES SORTED BY DISTRICT ORISSA

29 PONDICHERRY

- 29.1 LATENT DEMAND BY YEAR PONDICHERRY
- 29.2 CITIES SORTED BY RANK PONDICHERRY
- 29.3 CITIES SORTED BY DISTRICT PONDICHERRY

30 PUNJAB

- 30.1 LATENT DEMAND BY YEAR PUNJAB
- 30.2 CITIES SORTED BY RANK PUNJAB
- 30.3 CITIES SORTED BY DISTRICT PUNJAB

31 RAJASTHAN

31.1 LATENT DEMAND BY YEAR - RAJASTHAN



31.2 CITIES SORTED BY RANK - RAJASTHAN 31.3 CITIES SORTED BY DISTRICT - RAJASTHAN

32 SIKKIM

- 32.1 LATENT DEMAND BY YEAR SIKKIM
- 32.2 CITIES SORTED BY RANK SIKKIM
- 32.3 CITIES SORTED BY DISTRICT SIKKIM

33 TAMIL NADU

- 33.1 LATENT DEMAND BY YEAR TAMIL NADU
- 33.2 CITIES SORTED BY RANK TAMIL NADU
- 33.3 CITIES SORTED BY DISTRICT TAMIL NADU

34 TRIPURA

- 34.1 LATENT DEMAND BY YEAR TRIPURA
- 34.2 CITIES SORTED BY RANK TRIPURA
- 34.3 CITIES SORTED BY DISTRICT TRIPURA

35 UTTAR PRADESH

- 35.1 LATENT DEMAND BY YEAR UTTAR PRADESH
- 35.2 CITIES SORTED BY RANK UTTAR PRADESH
- 35.3 CITIES SORTED BY DISTRICT UTTAR PRADESH

36 UTTARAKHAND

- 36.1 LATENT DEMAND BY YEAR UTTARAKHAND
- 36.2 CITIES SORTED BY RANK UTTARAKHAND
- 36.3 CITIES SORTED BY DISTRICT UTTARAKHAND

37 WEST BENGAL

- 37.1 LATENT DEMAND BY YEAR WEST BENGAL
- 37.2 CITIES SORTED BY RANK WEST BENGAL
- 37.3 CITIES SORTED BY DISTRICT WEST BENGAL



38 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

38.1 DISCLAIMERS & SAFE HARBOR

38.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS



I would like to order

Product name: The 2023-2028 Outlook for Rare Disease Drugs in India Product link: https://marketpublishers.com/r/2C48946CF26FEN.html

Price: US\$ 595.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2C48946CF26FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

i iiot iiaiiio.	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970